Posted by Michael Wonder on 06 May 2021
ICER to assess treatment for severe asthma
6 May 2021 - Report will be subject of Midwest CEPAC meeting in November 2021; draft scoping document open to public comment until 27 May 2021.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of tezepelumab (AstraZeneca) for the treatment of severe asthma.
An FDA decision on tezepelumab is expected in late 2021 or early 2022.
